BEONE MEDICINES LTD-ADR (ONC) Stock Overview
USA - NASDAQ:ONC - US07725L1026 - ADR
ONC Key Statistics, Chart & Performance
The current stock price of ONC is 316.42 USD. In the past month the price decreased by -5.38%.
ONC Latest News, Press Relases and Analysis
ONC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.68 | 405.55B | ||
| AMGN | AMGEN INC | 13.7 | 160.87B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
| ARGX | ARGENX SE - ADR | 91.01 | 51.63B | ||
| INSM | INSMED INC | N/A | 35.04B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| NTRA | NATERA INC | N/A | 24.94B | ||
| BIIB | BIOGEN INC | 8.93 | 20.97B | ||
| GMAB | GENMAB A/S -SP ADR | 16.5 | 20.42B |
Related stock screener links
About ONC
Company Profile
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Company Info
BEONE MEDICINES LTD-ADR
c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor
Basel BASEL-STADT CH
Employees: 11075
Phone: 41616851900
BEONE MEDICINES LTD-ADR / ONC FAQ
What is the stock price of BEONE MEDICINES LTD-ADR today?
The current stock price of ONC is 316.42 USD. The price decreased by -0.5% in the last trading session.
What is the ticker symbol for BEONE MEDICINES LTD-ADR stock?
The exchange symbol of BEONE MEDICINES LTD-ADR is ONC and it is listed on the Nasdaq exchange.
On which exchange is ONC stock listed?
ONC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BEONE MEDICINES LTD-ADR stock?
14 analysts have analysed ONC and the average price target is 336.73 USD. This implies a price increase of 6.42% is expected in the next year compared to the current price of 316.42. Check the BEONE MEDICINES LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BEONE MEDICINES LTD-ADR worth?
BEONE MEDICINES LTD-ADR (ONC) has a market capitalization of 34.76B USD. This makes ONC a Large Cap stock.
How many employees does BEONE MEDICINES LTD-ADR have?
BEONE MEDICINES LTD-ADR (ONC) currently has 11075 employees.
What are the support and resistance levels for BEONE MEDICINES LTD-ADR (ONC) stock?
BEONE MEDICINES LTD-ADR (ONC) has a support level at 316.41 and a resistance level at 324.06. Check the full technical report for a detailed analysis of ONC support and resistance levels.
Is BEONE MEDICINES LTD-ADR (ONC) expected to grow?
The Revenue of BEONE MEDICINES LTD-ADR (ONC) is expected to grow by 39.3% in the next year. Check the estimates tab for more information on the ONC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BEONE MEDICINES LTD-ADR (ONC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONC, evaluating the profitability, health, valuation and growth aspects
- BEONE MEDICINES LTD-ADR (ONC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BEONE MEDICINES LTD-ADR (ONC) Sales and EPS estimates to see what analysts future expectations are.
- BEONE MEDICINES LTD-ADR (ONC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BEONE MEDICINES LTD-ADR (ONC) Insider and Institutional Ownership to learn about the owners and their transactions.
- BEONE MEDICINES LTD-ADR (ONC) Stock Chart to make your own analysis
- BEONE MEDICINES LTD-ADR (ONC) Latest news and press-releases to stay up to date.
Does BEONE MEDICINES LTD-ADR (ONC) stock pay dividends?
ONC does not pay a dividend.
When does BEONE MEDICINES LTD-ADR (ONC) report earnings?
BEONE MEDICINES LTD-ADR (ONC) will report earnings on 2025-11-12.
What is the Price/Earnings (PE) ratio of BEONE MEDICINES LTD-ADR (ONC)?
The PE ratio for BEONE MEDICINES LTD-ADR (ONC) is 5.11. This is based on the reported non-GAAP earnings per share of 61.88 and the current share price of 316.42 USD. Check the full fundamental report for a full analysis of the valuation metrics for ONC.
What is the Short Interest ratio of BEONE MEDICINES LTD-ADR (ONC) stock?
The outstanding short interest for BEONE MEDICINES LTD-ADR (ONC) is 18.4% of its float. Check the ownership tab for more information on the ONC short interest.
ONC Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ONC.
ONC Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ONC. The financial health of ONC is average, but there are quite some concerns on its profitability.
ONC Financial Highlights
Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of 61.88. The EPS increased by 217.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.68% | ||
| ROE | -6.15% | ||
| Debt/Equity | 0.26 |
ONC Forecast & Estimates
14 analysts have analysed ONC and the average price target is 336.73 USD. This implies a price increase of 6.42% is expected in the next year compared to the current price of 316.42.
For the next year, analysts expect an EPS growth of 123.23% and a revenue growth 39.3% for ONC